Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs
- PMID: 15741621
- DOI: 10.2106/JBJS.D.02192
Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs
Abstract
Background: Femoral head deformity is the most serious sequela of ischemic necrosis of the immature femoral head. The purpose of this study was to determine if a highly potent antiresorptive agent, ibandronate, can inhibit bone resorption during the repair of the infarcted femoral head and thus alter the repair process. We hypothesized that preservation of the trabecular framework by inhibiting osteoclastic bone resorption would minimize the development of deformity in a piglet model of ischemic necrosis. The effect of ibandronate on long-bone growth was also assessed.
Methods: Ischemic necrosis of the right femoral head was produced in twenty-four piglets by placing a ligature tightly around the femoral neck. The animals were divided into three groups according to whether they received saline solution, prophylactic treatment, or post-ischemia treatment. The contralateral, untreated femoral heads from the animals that had received saline solution served as the normal control group. At eight weeks, the femoral heads were assessed for deformity with radiography and for trabecular bone indices with histomorphometry. Also, the length of femur from the untreated side was measured on the radiographs and compared among the groups.
Results: Radiographic assessment showed that the epiphyseal quotient, determined by dividing the maximum height of the osseous epiphysis by the maximum diameter, was better preserved in the prophylactic (p < 0.001) and post-ischemia (p = 0.02) treatment groups than in the group treated with saline solution. Histomorphometric assessment also showed that the trabecular bone indices were better preserved in the prophylactic and the post-ischemia treatment groups than in the group treated with saline solution (p < 0.01). The mean femoral length on the untreated side of the animals treated with ibandronate was reduced compared with the length on the untreated side of the animals that had received saline solution (p </= 0.01).
Conclusions: Ibandronate preserves the trabecular structure of the osseous epiphysis and prevents femoral head deformity during the early phase of repair of ischemic necrosis in the piglet model.
Similar articles
-
RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis.J Bone Miner Res. 2006 Dec;21(12):1946-54. doi: 10.1359/jbmr.060905. J Bone Miner Res. 2006. PMID: 17002576
-
Development of flattening and apparent fragmentation following ischemic necrosis of the capital femoral epiphysis in a piglet model.J Bone Joint Surg Am. 2002 Aug;84(8):1329-34. doi: 10.2106/00004623-200208000-00006. J Bone Joint Surg Am. 2002. PMID: 12177261
-
Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity.J Bone Joint Surg Am. 2011 May 18;93(10):905-13. doi: 10.2106/JBJS.J.00716. J Bone Joint Surg Am. 2011. PMID: 21593365
-
Vasculature deprivation--induced osteonecrosis of the rat femoral head as a model for therapeutic trials.Theor Biol Med Model. 2005 Jul 5;2:24. doi: 10.1186/1742-4682-2-24. Theor Biol Med Model. 2005. PMID: 15996271 Free PMC article. Review.
-
Potential for bisphosphonate treatment in Legg-Calve-Perthes disease.J Pediatr Orthop. 2011 Sep;31(2 Suppl):S182-8. doi: 10.1097/BPO.0b013e318223b541. J Pediatr Orthop. 2011. PMID: 21857436 Review.
Cited by
-
Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats.BMC Musculoskelet Disord. 2006 Aug 4;7:63. doi: 10.1186/1471-2474-7-63. BMC Musculoskelet Disord. 2006. PMID: 16889666 Free PMC article.
-
Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial.Osteoporos Int. 2014 Jan;25(1):359-66. doi: 10.1007/s00198-013-2581-5. Epub 2013 Nov 22. Osteoporos Int. 2014. PMID: 24264372 Clinical Trial.
-
Bone marrow edema syndrome.Skeletal Radiol. 2009 May;38(5):425-36. doi: 10.1007/s00256-008-0529-1. Epub 2008 Jul 16. Skeletal Radiol. 2009. PMID: 18629460 Review.
-
Successful treatment of avascular bone necrosis of the knee with neridronate: a case report.Rheumatol Int. 2007 Jul;27(9):891-3. doi: 10.1007/s00296-007-0306-9. Epub 2007 Feb 7. Rheumatol Int. 2007. PMID: 17285278 No abstract available.
-
Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot.Rheumatol Int. 2013 Jun;33(6):1397-402. doi: 10.1007/s00296-012-2584-0. Epub 2012 Nov 10. Rheumatol Int. 2013. PMID: 23143557
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources